Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2043Neoplasms 1458Carcinoma, Non-Small-Cell Lung 1360Prostatic Neoplasms 1104Multiple Myeloma 870Leukemia, Myeloid, Acute 767Colorectal Neoplasms 710Neoplasm Metastasis 702Lung Neoplasms 696Melanoma 683Lymphoma 665Leukemia 595Lymphoma, Non-Hodgkin 592Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 530Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 483Recurrence 474Myelodysplastic Syndromes 424Lymphoma, Follicular 418Carcinoma, Renal Cell 410Head and Neck Neoplasms 407Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 374Hodgkin Disease 354Carcinoma, Hepatocellular 332Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

nicotinamide-beta-riboside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Muscle Weakness × Clear all
NCT03789175 2020-12-08

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
1 enrolled 7 charts

Neoplasms, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡